A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
What is Donanemab and how does it work? Both Donanemab and Lecanemab are antibody drugs that binds to amyloid, a protein which builds up in the brains of those with Alzheimer’s disease. By ...
Some results have been hidden because they may be inaccessible to you